放射肿瘤科医生对早期乳腺癌大分割放疗早期采纳的影响
该研究基于2004至2011年诊断为局限性乳腺癌并接受保乳手术加辅助放疗的22233例Medicare受益者,采用多层多变量logistic模型分析放射肿瘤科医生和地理区域对是否接受大分割放疗的影响。结果显示,个体放射肿瘤科医生(MOR 3.08)的影响大于地理区域(MOR 2.10)或临床人口学变量,且该影响从2004-2005年(MOR 2.82)增至2010-2011年(MOR 3.16),尽管2010年初已发表长期随机试验结果。
要点
- 个体放射肿瘤科医生对早期乳腺癌患者接受大分割放疗的可能性有强烈影响(MOR 3.08)。
- 医生影响从2004-2005年(MOR 2.82)增至2010-2011年(MOR 3.16),尽管长期随机试验结果已发表。
- 男性医生和治疗乳腺癌患者量最高的放射肿瘤科医生更少进行大分割放疗(P<.05)。
核心结论
- 个体放射肿瘤科医生强烈影响早期乳腺癌患者接受大分割放疗的可能性,且该趋势在长期等效数据发表后仍增加。
研究设计与样本
- 回顾性队列研究,纳入2004至2011年诊断的22233例接受保乳手术加辅助放疗的局限性乳腺癌Medicare受益者,采用按放射肿瘤科医生和地理实践区域聚类的多层多变量logistic模型。
主要发现
- 整个队列中2333例女性(10.4%)接受大分割放疗,未调整率从放射肿瘤科医生最低五分位的0.0%到最高五分位的30.4%。
- 多变量分析显示个体放射肿瘤科医生(MOR 3.08)对使用大分割的影响大于地理区域(MOR 2.10)或临床和人口学变量。
- 医生影响从2004至2005年(MOR 2.82)增至2010至2011年(MOR 3.16),尽管2010年初已发表长期随机试验结果。
- 男性医生和治疗乳腺癌患者量最高的放射肿瘤科医生更少进行大分割放疗(P<.05)。
临床怎么用
- 临床实践中应关注放射肿瘤科医生个体因素对早期乳腺癌大分割放疗采纳的影响,并针对相关医生因素开展干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Despite multiple randomized trials showing the efficacy of hypofractionated radiation therapy in early-stage breast cancer, the United States has been slow to adopt this treatment. The goal of this study was to evaluate the impact of individual radiation oncologists on the early adoption of hypofractionated radiation therapy for early-stage breast cancer. METHODS: We identified 22,233 Medicare beneficiaries with localized breast cancer that was diagnosed from 2004 to 2011 who underwent breast-conserving surgery with adjuvant radiation. Multilevel, multivariable logistic models clustered by radiation oncologist and geographic practice area were used to determine the impact of the provider and geographic region on the likelihood of receiving hypofractionated compared with standard fractionated radiation therapy while controlling for a patient's clinical and demographic covariates. Odds ratios (OR) describe the impact of demographic or clinical covariates, and the median OR (MOR) describes the relative impact of the individual radiation oncologist and geographic region on the likelihood of undergoing hypofractionated radiation therapy. RESULTS: Among the entire cohort, 2333 women (10.4%) were treated with hypofractionated radiation therapy, with unadjusted rates ranging from 0.0% in the bottom quintile of radiation oncologists to 30.4% in the top quintile. Multivariable analysis found that the individual radiation oncologist (MOR 3.08) had a greater impact on the use of hypofractionation than did geographic region (MOR 2.10) or clinical and demographic variables. The impact of the provider increased from the year 2004 to 2005 (MOR 2.82) to the year 2010 to 2011 (MOR 3.16) despite the publication of long-term randomized trial results in early 2010. Male physician and radiation oncologists treating the highest volume of breast cancer patients were less likely to perform hypofractionation (P<.05). CONCLUSIONS: The individual radiation oncologist strongly influenced the likelihood of a patient's receiving hypofractionated radiation therapy, and this trend increased despite the publication of long-term data showing equivalence to standard fractionation. Future research should focus on physician-related factors that influence this decision.
引用
- Boero IJ, Gillespie EF, Hou J, et al. The Impact of Radiation Oncologists on the Early Adoption of Hypofractionated Radiation Therapy for Early-Stage Breast Cancer. Int J Radiat Oncol Biol Phys. 2016. PMID: 28126306. doi:10.1016/j.ijrobp.2016.11.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。